Rebetol Oral Solution

Published Online: Monday, March 1, 2004

Schering-Plough Corp (Kenilworth, NJ) has announced the launch of Rebetol (ribavirin USP) Oral Solution for use in combination with Intron A (interferon alfa- 2b, recombinant) Injection for treating pediatric chronic hepatitis C. The combination of Intron A and Rebetol is indicated for the treatment of patients 3 years of age and older with compensated liver disease previously untreated with alpha interferon. Rebetol Oral Solution represents a new formulation of ribavirin USP, developed specifically to meet the needs of pediatric patients. It comes in bubble-gum flavor. For more information, visit www.scheringplough. com.

Latest Articles
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Having trouble getting your hands on FluMist?
Novartis is paying $390 million to settle charges that it paid kickbacks to pharmacies to encourage drug sales.
Latest Issues